Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma

NCT02107235 is registered in ClinicalTrials.gov with Traws Pharma, Inc. as lead sponsor.

NCT NCT02107235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma
Lead sponsor
Traws Pharma, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2014
Completion date
January 31, 2015
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, head and neck neoplasms